Sir Nigel Rudd has returned to Destiny Pharma Plc as chairman as the company advances its anti-infective portfolio towards registration and commercialisation. Sir Nigel was previously chairman of Destiny from 2010 to 2018 and led the company’s flotation on the London AIM market. His return follows the appointment of Chris Tovey as chief executive, effective 1 September. Mr Tovey joins Destiny from Jazz Pharmaceuticals Plc where he was chief operating officer.
Destiny Pharma announced the newest appointment on 25 July 2023.
Copyright 2023 Evernow Publishing Ltd